Last reviewed · How we verify
GnRHa
GnRHa is a Small molecule drug developed by Amsterdam UMC, location VUmc. It is currently FDA-approved. Also known as: Lucrin, Triprorelin acetate, goserelin, Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom.
GnRHa, marketed by Amsterdam UMC at VUmc, is a drug with a key composition patent expiring in 2028. The primary strength of GnRHa lies in its established market presence, leveraging the reputable research and clinical expertise of Amsterdam UMC. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | GnRHa |
|---|---|
| Also known as | Lucrin, Triprorelin acetate, goserelin, Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom |
| Sponsor | Amsterdam UMC, location VUmc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
- Body Composition Assessment in Transgender Population.
- Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients (NA)
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (PHASE3)
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PHASE3)
- A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) (PHASE4)
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GnRHa CI brief — competitive landscape report
- GnRHa updates RSS · CI watch RSS
- Amsterdam UMC, location VUmc portfolio CI
Frequently asked questions about GnRHa
What is GnRHa?
Who makes GnRHa?
Is GnRHa also known as anything else?
What development phase is GnRHa in?
Related
- Manufacturer: Amsterdam UMC, location VUmc — full pipeline
- Also known as: Lucrin, Triprorelin acetate, goserelin, Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing